IDEAYA Biosciences, Inc. (IDYA) is a Healthcare stock trading at $39.69 (as of 2026-08-21), with a market capitalization of $3.83B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
IDEAYA Biosciences develops targeted precision oncology therapeutics selected using molecular diagnostics, and it generates cash primarily through collaboration arrangements (it reported Collaboration Revenue).
Because IDEAYA is building products that are still in early clinical stages, its near-term profit model is more dependent on collaboration funding and the timing of research and development performance than on commercial product sales.
| Collab | $0.0B |
Business quality (Weak): Key valuation drivers are clinical execution and collaboration economics, but the latest-quarter financial snapshot shows essentially no revenue and a very large operating loss.
| Price | $39.69 |
| Market Cap | $3.83B |
| Price / Book | 3.19 |
| Price / Sales | 16.66 |
| FCF Yield | -2.3% |
| Revenue (TTM) | $218.71M |
| Net Margin | -52.0% |
| Revenue Growth (YoY) | 3024.4% |
| EPS Growth (YoY) | -61.9% |
| FCF Growth (YoY) | -70.8% |
| Altman Z-Score | 23.65 (safe) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | FMR LLC ($438.89M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Yujiro S. Hata |
| Employees | 131 |
| Country | US |
| IPO Date | 2019-05-23 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.